公开(公告)号：US20210253726A1

公开(公告)日：2021-08-19

申请号：US17133286

申请日：2020-12-23

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： C07K16/28 ,  A61K35/26 ,  A61K35/76 ,  C12N5/10 ,  C12N15/00 ,  C12N15/09 ,  A61K35/17 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725 ,  C07K14/705 ,  C07K16/44 ,  C12N5/0783

摘要： An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.
A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

公开(公告)号：US11337997B2

公开(公告)日：2022-05-24

申请号：US16084503

申请日：2017-03-15

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

公开(公告)号：US20190322755A1

公开(公告)日：2019-10-24

申请号：US16404165

申请日：2019-05-06

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji TAMADA ,  Yukimi SAKODA ,  Keishi Adachi

IPC分类号： C07K16/28 ,  C07K14/52 ,  A61K35/26 ,  C07K14/725 ,  C07K14/705 ,  C07K14/54 ,  A61K35/76 ,  C12N5/10 ,  C12N15/00 ,  C12N15/09 ,  A61K35/17 ,  C12N5/0783 ,  C07K16/44

摘要： An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

公开(公告)号：US11931381B2

公开(公告)日：2024-03-19

申请号：US17748889

申请日：2022-05-19

申请人： Yamaguchi University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： C12N5/10 ,  A61K35/17 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/09 ,  C12N15/79

CPC分类号： A61K35/17 ,  A61K39/0011 ,  C07K14/5418 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

公开(公告)号：US20240269174A1

公开(公告)日：2024-08-15

申请号：US18166672

申请日：2023-02-09

申请人： Yamaguchi University ,  National University Corporation Tottori University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi ,  Takafumi Nakamura

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/521 ,  C07K14/5418 ,  C07K14/7051

摘要： The present disclosure provides a composition comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and its use thereof.

公开(公告)号：US20240226157A1

公开(公告)日：2024-07-11

申请号：US18424245

申请日：2024-01-26

申请人： Yamaguchi University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

CPC分类号： A61K35/17 ,  A61K39/0011 ,  C07K14/5418 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

公开(公告)号：US10316102B2

公开(公告)日：2019-06-11

申请号：US15513870

申请日：2015-10-06

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K48/00 ,  C12N15/00 ,  C12N15/63 ,  C07K16/28 ,  A61K35/26 ,  A61K35/76 ,  C12N5/10 ,  C12N15/09 ,  A61K35/17 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725 ,  C07K14/705 ,  C07K16/44 ,  C12N5/0783 ,  C07K19/00 ,  C07K14/47

摘要： An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.

公开(公告)号：US11617765B2

公开(公告)日：2023-04-04

申请号：US16754645

申请日：2018-10-09

申请人： YAMAGUCHI UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi ,  Takafumi Nakamura

IPC分类号： A61K35/17 ,  A61P35/00

摘要： An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

公开(公告)号：US20220273723A1

公开(公告)日：2022-09-01

申请号：US17748889

申请日：2022-05-19

申请人： Yamaguchi University

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/79

摘要： It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.

公开(公告)号：US10906984B2

公开(公告)日：2021-02-02

申请号：US16404165

申请日：2019-05-06

申请人： YAMAGUCHI UNIVERSITY

发明人： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC分类号： A61K48/00 ,  C12N15/00 ,  C12N15/63 ,  C07K16/28 ,  A61K35/26 ,  A61K35/76 ,  C12N5/10 ,  C12N15/09 ,  A61K35/17 ,  C07K14/52 ,  C07K14/54 ,  C07K14/725 ,  C07K14/705 ,  C07K16/44 ,  C12N5/0783 ,  A01K67/00 ,  C07K19/00 ,  C07K14/47

摘要： An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells.
A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.